COMPOUND PROFILE / PEPTIDES & ANALOGUES
Avorelin.
Research draftAvorelin is a long-acting GnRH agonist investigated in prostate cancer, not a growth-hormone-releasing peptide.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Avorelin is a long-acting GnRH agonist investigated in prostate cancer, not a growth-hormone-releasing peptide.
Mechanism
Prolonged stimulation of GnRH receptors suppresses gonadotropin and testosterone responses after an initial phase.
Human research
Depot research demonstrated hormone suppression in patients with prostate cancer.
Preclinical & other research
Primate endocrine work examined effects of testosterone suppression.
Safety & unknowns
Hormonal suppression has substantial reproductive and metabolic implications; it is not a wellness GH booster.
Regulatory status
Investigational evidence must be matched to the avorelin depot formulation.
Reported use & evidence
The supplied Avorelin profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.